Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and mount potent anti-tumor responses. These properties make them an attractive candidate for next-generation ...
Apr 30, 2026
0
48
Chimeric antigen receptor (CAR) T-cell therapy is one of oncology's most powerful ideas: Harvest a cancer patient's own immune cells, genetically engineer them to recognize tumor cells, multiply them in a laboratory and reinject ...
Apr 29, 2026
0
10
CAR-T cell therapy works well in blood cancers, but many patients still become resistant. A key reason is the presence of CAR-T regulatory T cells (CAR-Tregs), which weaken immune responses. Therefore, selectively targeting ...
Apr 29, 2026
0
9
A key molecular dynamic could be the key to fighting tumors while allowing patients to still receive life-saving cell transplantation, according to the latest finding published by a team of scientists from the Hackensack ...
Apr 28, 2026
0
6
Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited tools at their disposal to predict who is most likely to benefit or suffer from a particular myeloma ...
Apr 27, 2026
0
4
Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B-cell lymphoma patients than the widely used International Prognostic Index. By identifying patients ...
Apr 22, 2026
0
1
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II ...
Apr 20, 2026
0
6
For the first time, scientists have used a modern cell therapy called CAR-T to treat a patient with three different life-threatening autoimmune diseases that had resisted years of treatment. The patient, who once required ...
Apr 9, 2026
0
31
A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine researchers. The approach equips ...
Mar 24, 2026
0
18
Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet how metabolic stress ...
Mar 18, 2026
0
11
